Back to Journals » OncoTargets and Therapy » Volume 10

Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas

Authors Ye ZH, Gao L, Wen DY, He Y, Pang YY, Chen G

Received 10 January 2017

Accepted for publication 21 February 2017

Published 21 March 2017 Volume 2017:10 Pages 1711—1723

DOI https://doi.org/10.2147/OTT.S132120

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Ingrid Espinoza

Zhi-hua Ye,1,* Li Gao,1,* Dong-yue Wen,2 Yun He,2 Yu-yan Pang,1 Gang Chen1

1Department of Pathology, 2Department of Ultrasonography, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China

*These authors contributed equally to this work

Background: IRAK1 has been reported to play an essential role in the development of multiple cancers. However, the clinical significance of IRAK1 in hepatocellular carcinoma (HCC) and the underlying molecular mechanism remain unclear. Therefore, we aimed to investigate the role of IRAK1 in the pathogenesis of HCC in this study.
Materials and methods: HCC tissues and para-carcinoma tissues were collected for immunohistochemistry (IHC) analysis to evaluate IRAK1 expression. Data of IRAK1 expression were downloaded from the cancer genome atlas (TCGA) for analyzing the clinical significance of IRAK1. Receiver operating characteristic (ROC) curve and survival analyses were carried out to assess the diagnostic and prognostic significance of IRAK1 in IHC and TCGA data. Additionally, we investigated the alteration of IRAK1 gene in HCC from cBioPortal to generate a network of the interaction between IRAK1 and the neighboring genes. The influence of IRAK1 gene alteration on the prognosis of HCC patients was evaluated by survival analysis.
Results: Analysis of both IHC and TCGA data revealed a significant upregulation of IRAK1 in HCC tissues. The IHC analysis revealed there was an increasing trend in IRAK1 expression among normal liver tissues, liver cirrhosis tissues, para-carcinoma tissues and HCC tissues. The ROC curves for IHC and TCGA data demonstrated that IRAK1 exhibited a significant diagnostic value for HCC. Moreover, IRAK1 expression was observed to be associated with tumor size, metastasis and T-stage. The survival analysis indicated that the upregulation of IRAK1 predicted a worse overall survival of HCC. Additionally, data from cBioPortal confirmed that 29% of HCC tissues possessed an alteration of the IRAK1 gene.
Conclusion:
IRAK1 may act as an oncogene in the development of HCC with its overexpression in HCC. Moreover, IRAK1 might serve as a promising diagnostic and therapeutic target for HCC.

Keywords: IRAK1, hepatocellular carcinoma, immunohistochemistry, RNA-seq, diagnosis, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma

Liang HW, Ye ZH, Yin SY, Mo WJ, Wang HL, Zhao JC, Liang GM, Feng ZB, Chen G, Luo DZ

OncoTargets and Therapy 2017, 10:3405-3419

Published Date: 11 July 2017

Human papillomavirus as a potential risk factor for gastric cancer: a meta-analysis of 1,917 cases

Zeng ZM, Luo FF, Zou LX, He RQ, Pan DH, Chen X, Xie TT, Li YQ, Peng ZG, Chen G

OncoTargets and Therapy 2016, 9:7105-7114

Published Date: 17 November 2016

Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study

Huang WT, Wang HL, Yang H, Ren FH, Luo YH, Huang CQ, Liang YY, Liang HW, Chen G, Dang YW

OncoTargets and Therapy 2016, 9:5163-5180

Published Date: 22 August 2016

Clinicopathological role of miR-30a-5p in hepatocellular carcinoma tissues and prediction of its function with bioinformatics analysis

Huang WT, Chen ZX, He RQ, Wu YZ, Yin SY, Liang XN, Chen G, Yang H, Peng ZG, Yang LH

OncoTargets and Therapy 2016, 9:5061-5071

Published Date: 12 August 2016

Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases

Zhang Y, Luo J, He RQ, Huang WT, Li ZY, Li P, Dang YW, Chen G, Li SK

OncoTargets and Therapy 2016, 9:4959-4968

Published Date: 10 August 2016

Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis

Li JJ, Liang L, Liu YR, Luo YH, Liang XN, Luo DZ, Feng ZB, Dang YW, Yang LH, Chen G

OncoTargets and Therapy 2016, 9:1721-1734

Published Date: 21 March 2016